COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles and in vitro antibody-dependent enhancement
COVID-19 vaccination induces DENV cross-reactive antibodies with a distinct isotype profile and distinct ADE compared with natural dengue infection. Due to low Fc-affinity these antibodies likely do not pose a threat of dengue. These findings highlight the importance of considering off-target immunity and ADE risk in future vaccine design.
Authors
- Ching‐Yen Tsai (ORCID: https://orcid.org/0000-0001-7964-6661)
- Kuei-Ching Hsiung (ORCID: https://orcid.org/0000-0002-2107-6368)
- Shu‐Min Lin (ORCID: https://orcid.org/0000-0002-0834-564X)
- Sebastian Reinig
- Po-Kai Chen (ORCID: https://orcid.org/0009-0006-7830-0590)
- Etsuro Ito (ORCID: https://orcid.org/0000-0002-1877-6566)
- Shin‐Ru Shih (ORCID: https://orcid.org/0000-0003-4874-401X)
- Sheng‐Yu Huang (ORCID: https://orcid.org/0000-0002-7626-688X)
- Ing‐Kit Lee
- Chin Hwa Kuo
Institutions
- Waseda University (JP)
- Kaohsiung Medical University (TW)
- Chang Gung University (TW)
- United Hospital (US)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Japan Bio Products (Japan) (JP)
- Kaohsiung Municipal Hsiao-Kang Hospital (TW)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1683070
- Citations
- 1
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- Ministry of Education, India
- Chang Gung Medical Foundation
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases